[Content Courtesy: Inside Indiana Business]
This year is slated to be a big one for Indianapolis-based Eli Lilly and Co. (NYSE: LLY) as the pharmaceutical giant plans to release four new medicines to the public, with even more in the pipeline. Lilly is also moving forward with its plans to anchor the LEAP Lebanon Innovation District in Boone County with a $2.1 billion manufacturing campus that could create up to 500 jobs.
CEO Dave Ricks told Inside INdiana Business Host Gerry Dick the momentum was created by tailwinds in 2022 and earlier.
“In our business, it’s all about what you invented lately, and can it grow and drive the top line? And we’re in a privileged position in that way, because we have been very successful in last five or six years launching new medicines,” Ricks said. “And we are poised…to launch four more in the next 12 months, having just launched maybe one of the most important products in our history called Mounjaro for diabetes just late last year.”
Lilly’s pipeline of medicines covers a variety of conditions, including leukemia, diabetes, psoriasis, asthma and obesity.
Ricks said in addition to investing in drug development efforts, Lilly is also investing in manufacturing in a way the company hasn’t done before. Lilly has five new sites in the works, including two in the LEAP district.
The company earlier this month told the Lebanon Planning Commission it has plans for a total of 12 buildings on its 600-acre campus, ranging from a 3,200-square-foot visitors center to the two, three-story, 330,000-square-foot manufacturing facilities.